BMD at the femoral neck remained stable in both groups.
with growth hormone deficiency (GHD) has shown favorable effects on body composition, lipid profile and bone  2001 by the International Society of Nephrology mineral density [20] [21] [22] , only supraphysiological doses
The study was prospective, randomized, double blind, and placebo controlled (GH/placebo). The patients reof GH and IGF-I induced a net decrease in total urea nitrogen appearance in CRF patients [23] [24] [25] . Also, two ceived either recombinant GH (Genotropin R by Pharmacia, Stockholm, Sweden) or placebo, which was suprecently published studies demonstrated improvements in anthropometric measurements, a decrease in prediaplied in identical cartridges for reconstitution with 1 mL of water for injection with 3 mg of m-cresol. The rhGH lytic BUN levels, and an increase in serum albumin concentrations [26, 27] . dose was 0.125 IU/kg (40.5 g/kg) three times a week during the first four weeks and 0.25 IU/kg (81 g/kg) The aim of the present study was to extend the hitherto described observations of the effects of supraphysiological thereafter three times a week after each dialysis session. In five of these patients, the dose had to be reduced rhGH doses in malnourished patients on chronic hemodialysis with low IGF-I concentrations. These low IGF-I temporarily (1 week) by 50% because of adverse events. Adverse events. Five patients developed a shunt thromlevels may indicate profound GH resistance as well as reduced nutrient intakes. In addition to nutritional and bosis (3 patients receiving GH and 2 placebo). Six patients (5 patients receiving GH, 1 placebo) suffered from anthropometric parameters, parameters of bone metabolism and bone mineral density (BMD), function of polyarthralgias, and one patient receiving GH suffered from newly developed headache. One patient who received morphonuclear leukocytes, and quality of life (QoL) were determined in a double blind, placebo-controlled, threeplacebo died because of cardiovascular failure after one month. month trial.
Biochemical, immunological, and anthropometric measurements were performed in all subjects after the long METHODS dialysis-free period. Blood was drawn before and after the Patients first dialysis of the week and again before the next dialysis for urea determinations used to calculate urea kinetics Nineteen malnourished patients (10 females and 9 males) with a mean age of 59.3 Ϯ 13.4 years on chronic (URR, PCR, Kt/V). Blood hemoglobin, blood glucose, and serum biochemistries were analyzed by routine methhemodialysis entered this study after informed consent was given. Patients had to be on chronic hemodialysis for ods. Serum C reactive protein (CRP) was measured by using an immunonephelometric method (Tina-quant; at least six months. Patients fulfilling at least three out of the four following criteria were included into the study:
Bö hringer Mannheim, Mannheim, Germany). Albumin, prealbumin, cholesterol, cholinesterase, protein, and transserum cholesterol and transferrin levels Ͻ200 mg/dL, serum albumin concentrations Ͻ41 g/L, and a body weight ferrin were determined by nephelometry (Nephelometer BNA II; Behring Diagnostics, Marburg, Germany). of Ͻ80% of the optimal body weight. The protocol was approved by the Human Ethics Committee of the UniInsulin-like growth factor I (IGF-I) was quantified by a radioimmunoassay (RIA). Serum samples were exversity of Vienna. Eighteen patients finished the threemonth study. One patient (receiving placebo) died betracted by acid-ethanol method and diluted 1:20 prior to determination. IGF-I rabbit antiserum was provided cause of cardiovascular failure after one month. Chronic hemodialysis was performed three times weekly in all by the Hormone Distribution Program of NIDDK (Bethesda, MD, USA) and was used at a final dilution of patients using bicarbonate and biocompatible high (N ϭ 10) or low-flux dialyzers (N ϭ 9), the duration was four 1:5000. The international reference preparation rhIGF-I 87/518 was from NIBSC (UK) and was used as standard. hours in most patients and was not changed during the observation period.
The tracer, prepared by iodination of recombinant IGF-I and purified by HPLC, was from Amersham (Little ChalChronic renal failure was due to various etiologies including polycystic kidney disease (N ϭ 1), chronic glomerfont, Buckinghamshire, UK). The detection limit of the assay was 0.1 ng/tube. The intraassay coefficient of variaulonephritis (N ϭ 10), chronic pyelonephritis (N ϭ 4), diabetic and/or hypertensive nephropathy and nephrotion was 11.8% at 153 ng/mL, and the interassay coefficient of variation at 182 ng/mL was 9.4%. The RIA for angiosclerosis (N ϭ 4). Two of the patients were type I diabetics requiring insulin. One patient was a type II IGFBP-3 (Miadiagnostik, Germany) utilized a specific high polyclonal rabbit antibody. The tracer was prepared diabetic. No patient had a history of a malignoma. Ten patients had a history of cardiovascular disease.
by direct radioiodination of pure IGFBP-3 and standards refer to a stable derivate of IGFBP-3 with a molecular Study design and treatment schedule weight of 30.5 kD. Serum was considerably diluted before analysis, but no extraction step was required. The The hypothesis to be tested by this study was to examine whether rhGH therapy in pharmacological doses imsensitivity of the assay was 0.006 ng/mL. Serum levels of intact parathyroid hormone (PTH) proves nutritional and anthropometric parameters or has some impact on bone metabolism or granulocyte func-(Nichols Institute Diagnostics, San Juan Capistrano, CA, USA) and serum osteocalcin (OC; CIS International, tion in hemodialysis patients. available RIA (Orion Diagnostica, Espoo, Finland). The intra-assay CVs for PICP, PIIINP, and ICTP were 2.7, 2.5, and 2.8%, respectively. The interassay CVs were 6.6, chest, thoracal-midaxillary, suprailiacal, paraumbilical, 3.2, and 4.1%, respectively. An ELISA (Osteometer, subscapular, triceps, front thigh (suprapatellar), biceps BioTech, Herlev, Denmark) was performed to deterand popliteal [34] . Skinfolds were measured to the nearmine the serum Crosslaps. est 0.2 mm, as the mean of three readings by the same Bone densitometry investigator to eliminate the intertester variability. Measurements were performed after hemodialysis. Total X-ray films of the lumbar and thoracic spine and the body fat (TBF) was calculated from the formula of Allen hip were obtained to exclude the possibility of spine fracet al [35] . The lean body mass (LBM) was derived by tures or severe osteoarthritis. BMD was measured using subtracting TBF from body mass. dual-energy x-ray absorptiometry (DEXA) on a QDR 2000 TM device (Hologic R, Waltham, MA, USA). Sites Quality of life of measurements were the lumbar spine (L1 to L4) and the left femoral neck. The in vivo precision of DEXA Health-related quality of life (QoL) was measured was 0.71% for the lumbar spine and 1.0% for the femoral using the self-rating questionnaire the Nottingham neck.
Health Profile (NHP I), where patients had to answer 38 questions concerning problems with emotional reaction, Preparation of PMNLs sleep, energy, pain, physical mobility, and social life, Polymorphonuclear leukocytes (PMNLs) were pre- [36, 37] , and the AGHDA, which is a self-administered pared from 10 mL heparinized (10 U/mL Liquemin; Roche, questionnaire designed specially to evaluate quality of Basle, Switzerland) whole blood as described by Harbeck life in adults with GHD. This questionnaire consists of et al [28] . Leukocyte-rich plasma was obtained using a 25 unidimensional items measuring the quality of life Ficoll-Hypaque gradient and was layered on a Percoll aspects that are affected by GHD [38, 39] . Responses gradient. This was centrifuged at 500 ϫ g for 25 minutes are of the yes/no type. High scores reflect a bad QoL at room temperature. PMNLs were harvested in the suin both questionnaires and improvements in QoL are pernatant and then washed twice with Hank's buffered reflected by a decrease in the scores. saline (HBSS) with Ca 2ϩ and Mg 2ϩ . Viability was tested with trypan blue and was always greater than 90%.
Statistical methods

Phagocytosis. Phagocytosis and intracellular killing of
The statistical analysis was performed using SAS softopsonized Escherichia coli cells were performed as deware (version 6.09E). We employed the GLM procedure scribed by Moiola [29] .
(to take into account the possible unbalanced data) for Determination of PMNL (Ca 2ϩ ). Measurements of detecting deviations in the course of time using the numresting and stimulated (Ca 2ϩ ) of PMNLs were performed ber of the patient and the time as class variables, but using the fluorescent indicator Fura 2/AM (Sigma, Muspecifying the number of the patient as a random effect nich, Germany) as described previously [30, 31] .
(that is, considering joint observations). We used Tukey's Determination of PMNL glucose uptake. Glucose upstudentized range test (HSD) on the means of the main take was determined as described by McCall et al [32] . effects (that is, time) to locate the points in time where Anthropometric measurements significant deviations occur. Variables of interest were described by their means and standard deviations (SD) Height was measured to the nearest 0.5 cm and body and differences were considered significant with P Ͻ 0.05. mass to the nearest 0.1 kg. The body mass index was calculated as weight in kg divided by height in m 2 ; body surface area was computed from the equation of DuBois RESULTS and DuBois [33] . Body composition assessment was dePatient characteristics are shown in Table 1 . Baseline termined by skinfold thickness measurement using a Holtain caliper at 10 sites: cheek (temporal), chin, pectoralnutritional and anthropometric parameters as well as Serum markers of bone formation (PICP, OC, AP) as well as markers of bone resorption (ICTP, serum Crosslaps) and parathyroid hormone (PTH) were evalparameters of bone metabolism and PMNL function uated during these three months. A significant increase were comparable in both groups (Tables 2 and 3). in PICP from 250.1 Ϯ 112.6 to 478.5 Ϯ 235.2 g/L (P Ͻ The IGF-I concentration increased significantly from 0.01) was observed, the increase in OC after 3 months 169.2 Ϯ 95.6 to 262.9 Ϯ 144.4 ng/mL (P Ͻ 0.01) after was statistically not significant (Fig. 2) . PIIINP, a nonthree months in the group receiving rhGH, whereas IGF-I bone specific marker of collagen production, rose siglevels showed no significant changes in the placebo nificantly during the three months of rhGH therapy (9.9 Ϯ group. IGF-BP3 levels increased only slightly after three 4.9 to 14 Ϯ 6.5 ug/L, P Ͻ 0.01). In parallel with the months in the therapy group (P ϭ NS; Fig. 1) .
markers of bone formation ICTP as a marker of bone Serum albumin, prealbumin, transferrin, cholesterol, resorption showed a slight, but not significant increase HDL cholesterol, cholinesterase, as well as predialytic after three months of therapy (50.3 Ϯ 18.5 vs. 70.0 Ϯ creatinine and blood urea nitrogen (BUN) showed no 39.5 g/L, P ϭ NS; Fig. 2 ), whereas serum Crosslaps significant changes during the three months course in the remained stable during the whole period. Since most placebo group as well as in the therapy group (Table 2) .
of the patients in this study suffered from a secondary Percent total body fat (%TBF) was slightly, but not sighyperparathyroidism, intact PTH was already elevated nificantly, reduced in the GH-treated patients, whereas at baseline and rose from 198.0 Ϯ 139.2 to 293.4 Ϯ 144.8 lean body mass (LBM) remained stable in both groups. ng/mL (P ϭ NS) in the treatment group; serum calcium (Table 3) . CRP levels were slightly elevated in both groups concentrations were comparable at baseline and after (GH-treated group: 0.7 Ϯ 0.3 vs. 0.9 Ϯ 0.4 mg/dL, placebo three months in both groups. BMD of the lumbar spine group: 2.2 Ϯ 0.9 vs. 2.6 Ϯ 1.2 mg/dL after 3 months)
showed a significant decrease after three months in the without correlation to the nutritional and anthropomettreatment group (0.8 Ϯ 0.17 vs. 0.77 Ϯ 0.16 g/cm 2 , P Ͻ ric parameters. Blood glucose levels rose in two patients 0.01), whereas it remained stable in the femoral neck (receiving rhGH) with pre-existing diabetes requiring an during the whole period (Fig. 3) . At baseline phagocytic activity was lower in the group increase in the insulin dose of one patient with diabetes 
DISCUSSION
In the past ten years, several studies have shown significant effects of rhGH substitution therapy on body composition (LBM, %TBF) [20] [21] [22] , bone mineral density (BMD) [40, 41] and quality of life in adult patients in hypophysectomized rats [42] . In accordance with these results in GHD patients, short-and long-term studies with rhGH in uremic patients on chronic hemodialysis receiving rhGH, but increased significantly after three months (Fig. 4) . In contrast, no changes were observed or continuous ambulatory peritoneal dialysis (CAPD) have recently reported an increase in serum albumin in the placebo-treated patients. None of the other tests of PMNL function (metabolic burst, intracellular killing, concentrations and favorable effects on several anthropometric parameters and handgrip strength [23] [24] [25] [26] [27] . In glucose uptake, intracellular calcium concentration) was affected by GH (data not shown).
our placebo-controlled, double-blind study, over a period of three months no changes in nutritional and anthropoThe QoL of these patients improved after three months of rhGH therapy as evidenced by a decrease in mean metric parameters were observed despite a significant increase in IGF-I levels. However, rhGH therapy inQoL AGHDA (Quality of Life Assessment of Growth Hormone Deficiency in Adults) score of 1.4 points, duced an increase in bone turnover combined with a decrease in BMD at the lumbar spine, an increase in whereas the AGHDA score increased by 2.4 points in the placebo group. NHP I showed no changes in either phagocytic activity as well as a slight improvement in quality of life. group during the three months (Fig. 5) . Patients with CRF have a high incidence of proteinfold risk in mortality [5] . During the three months of GH therapy no significant changes in the nutritional or calorie malnutrition, and malnutrition is a strong predictor of morbidity and mortality in these individuals [5] .
the anthropometric parameters were observed. In contrast to previously published studies in patients on Most research on anabolic hormones in catabolic conditions has recently been performed with rhGH. While chronic hemodialysis, where an increase in serum albumin concentrations and improvement in anthropometric CRF patients have normal or even slightly elevated GH levels and sometimes also normal IGF-I levels, resistance parameters has been described [26, 27] , our patients had markedly lower IGF-I levels before and during therapy to the anabolic actions of IGF-I in the skeletal muscle has been described [14, 17] . Beside metabolic acidosis with rhGH. This might explain the discrepant findings to some extent, since our patients might have exhibited [18] , inflammation, and reduced nutrient intakes [19] , this resistance in the skeletal muscle has been attributed a more severe form of malnutrition and catabolism resulting in more pronounced GH-resistance. This would to defects in cellular signaling with a defect in tyrosine kinase activity of the IGF-I receptor and to the presence be in line with preliminary data showing that malnourished patients who were severely ill and eating poorly of circulatory inhibitors such as elevated IGFBPs. In chronic renal failure, IGFBP-3 is usually elevated reduring GH therapy demonstrated almost no improvement in nitrogen balance and albumin concentrations, sulting in reduced IGF-I bioavailability [43, 44] . Therefore, the rationale for treating CRF patients on hemodidespite positive effects on bone turnover [49] . Nutritional and metabolic factors affect the immune alysis with rhGH was the use of pharmacological GH doses in an attempt to overcome GH resistance and to system of uremic patients and malnutrition is known to impair the function of PMNL and cellular host defense promote protein anabolism. Higher doses and/or higher frequency of GH applications might have led to higher [50, 51] , resulting in an increased incidence of infections. Infections are the most common cause for hospitalization IGF-I concentrations, but more likely to an increase in side effects. and the second leading cause of death in this population [5, 52] . Increased resting levels of intracellular calcium, The nutritional status of our patients was assessed using several parameters including serum albumin, premainly due to elevated parathyroid levels, iron overload, zinc deficiency, malnutrition and circulating plasma inalbumin, cholesterol, HDL cholesterol, cholinesterase, IGF-I, transferrin, predialytic creatinine, and BUN, as hibitors appear to be responsible for the impaired cellular host defense with impaired PMNL function, impaired well as anthropometric parameters (LBM, %TBF, and skinfold thickness) [45] [46] [47] [48] . Among those, serum albuphagocytosis, and decreased glucose uptake [50, 51] . There is also clinical evidence for profound defects in the min levels correlated best with morbidity and mortality, with concentrations below 35 g/L associated with a twospecific immune defense in uremia, such as high suscepti-bility to viral infections, a deficient response of T-lym-GHD, we speculate that prolonged GH therapy leads to an increase in BMD. phocytes and significantly depressed specific antibody
In conclusion, we have shown that pharmacological responses. GH was able to increase the activity of cytodoses of rhGH increase IGF-I concentrations and induce toxic T-lymphocytes in vitro and of natural killer cell an increase in bone turnover with a decrease in BMD activity in vivo, to prime macrophages for superoxide of the lumbar spine. In addition in our malnourished anion release and augment respiratory burst in neutrohemodialysis patients there was an enhanced phagocytic phils [42] . In GH-deficient patients the diminished natuactivity of PMNLs and a slight improvement in QoL. ral killer-cell activity could be partially restored by GH.
However, no changes in nutritional and anthropometric In the present study, GH stimulated phagocytic activity parameters could be detected. Thus, in our severely malof PMNLs significantly after three months of therapy, nourished patients, even supraphysiological doses of GH which could be of clinical relevance in patients with were only partially able to overcome GH resistance. chronic renal failure requiring renal replacement therapy. However, other parameters of granulocyte function ACKNOWLEDGMENT (intracellular killing, glucose uptake, metabolic burst, and intracellular calcium concentrations) were not af-
